Signalisation JAK/STAT
Les inhibiteurs de la signalisation JAK/STAT sont des composés qui perturbent la voie des kinases Janus (JAK) et du transducteur et activateur de transcription (STAT), impliquée dans la signalisation des cytokines, la croissance cellulaire et la réponse immunitaire. Ces inhibiteurs sont des outils importants pour étudier la régulation de cette voie et son rôle dans diverses maladies, notamment les cancers, les troubles immunitaires et les affections inflammatoires. Les inhibiteurs JAK/STAT sont également en cours de développement en tant que thérapies ciblées pour ces maladies. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de haute qualité de la signalisation JAK/STAT pour soutenir vos recherches en biologie moléculaire, oncologie et immunologie.
Sous-catégories appartenant à la catégorie "Signalisation JAK/STAT"
321 produits trouvés pour "Signalisation JAK/STAT"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ilginatinib hydrochloride
CAS :<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C21H21ClFN7Degré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :425.89N-(3-Aminopropyl)cyclohexylamine
CAS :<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Formule :C9H20N2Degré de pureté :98.05% - 98.82%Couleur et forme :Pale Yellow Clear LiquidMasse moléculaire :156.2685Pim-1 kinase inhibitor 8
CAS :<p>Pim-1 kinase inhibitor 8 is a Pim-1 kinase inhibitor with anticancer activity that inhibits cell migration and can be studied in breast cancer.</p>Formule :C14H17N3O3Degré de pureté :99.81%Couleur et forme :SoildMasse moléculaire :275.3TAK-901
CAS :<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Formule :C28H32N4O3SDegré de pureté :99.02% - 99.59%Couleur et forme :SolidMasse moléculaire :504.64KT-333
CAS :<p>KT-333 is a potent, highly selective, heterobifunctional degrader of STAT3 for the treatment of a variety of STAT3-dependent pathologies, antitumor.</p>Formule :C60H74ClN10O14PSDegré de pureté :98.12%Couleur et forme :SolidMasse moléculaire :1257.78Gusacitinib
CAS :<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Formule :C24H28N8O2Degré de pureté :98.06% - 99.94%Couleur et forme :SolidMasse moléculaire :460.53Delgocitinib
CAS :<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Formule :C16H18N6ODegré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :310.35Ilginatinib
CAS :<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C21H20FN7Degré de pureté :98.4% - 99.01%Couleur et forme :SolidMasse moléculaire :389.43Ilginatinib maleate
CAS :<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C25H24FN7O4Degré de pureté :99.74% - 99.82%Couleur et forme :SolidMasse moléculaire :505.5Golidocitinib
CAS :<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Formule :C25H31N9O2Degré de pureté :98.87% - 99.88%Couleur et forme :SolidMasse moléculaire :489.57Bromisoval
CAS :<p>Bromisoval (Isobromyl) is a mild hypnotic and sedative with potential toxicity.</p>Formule :C6H11BrN2O2Degré de pureté :98.86%Couleur et forme :SolidMasse moléculaire :223.07Nimucitinib
CAS :<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Formule :C25H26F2N6O2Degré de pureté :98.71%Couleur et forme :SoildMasse moléculaire :480.51Brepocitinib P-Tosylate
CAS :<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Formule :C25H29F2N7O4SDegré de pureté :99.82% - 99.97%Couleur et forme :SolidMasse moléculaire :561.6JAK2 Inhibitor V
CAS :<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Formule :C23H24N2ODegré de pureté :98.36% - 99.15%Couleur et forme :SolidMasse moléculaire :344.45WDR5-IN-6
CAS :<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Formule :C13H8Cl2N2O2SDegré de pureté :99.69%Couleur et forme :SoildMasse moléculaire :327.19Uzansertib phosphate
CAS :<p>Uzansertib phosphate (INCB053914 phosphate) is an orally active, ATP-competitive inhibitor of pan-PIM kinase, inhibiting PIM1, PIM2 and PIM3.</p>Formule :C26H29F3N5O7PDegré de pureté :99.75% - 99.79%Couleur et forme :SolidMasse moléculaire :611.51STAT4-IN-1
<p>STAT4-IN-1 is a STAT4 inhibitor with a Ki of 0.35 μM. It holds promise for research into autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes.</p>Couleur et forme :Odour SolidPM-81I
CAS :<p>PM-81I: Potent STAT6 inhibitor for allergic and pulmonary conditions, cancer research. Reduces STAT6 phosphorylation.</p>Formule :C43H58F2N3O10PCouleur et forme :SolidMasse moléculaire :845.91Pim-1 kinase inhibitor 11
<p>Pim-1 kinase inhibitor 11 (10f) is an inhibitor of PIM-1 with an IC50 value of 0.18 μM. It exhibits anticancer activity by inducing apoptosis and causing cell cycle arrest.</p>Couleur et forme :Odour SolidJAK-IN-15
CAS :<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formule :C22H23FN4O3SCouleur et forme :SolidMasse moléculaire :442.51JAK-2/3-IN-1
CAS :<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Formule :C20H12ClN3OCouleur et forme :SolidMasse moléculaire :345.79Eflepedocokin alfa
CAS :<p>Eflepedocokin alfa is a recombinant IL-22/IgG2-Fc protein, potentially protecting cells and enhancing immune function and tissue repair.</p>Couleur et forme :LiquidAS2553627
CAS :<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Formule :C18H19N5OCouleur et forme :SolidMasse moléculaire :321.38JAK1/TYK2-IN-1
CAS :<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formule :C18H20F3N7OCouleur et forme :SolidMasse moléculaire :407.401AK-2292
<p>AK-2292: potent STAT5 PROTAC degrader, DC50 0.10 μM, degrades STAT5A/B, may shrink leukemia tumors in mice.</p>Formule :C52H54F2N7O10PS2Couleur et forme :SolidMasse moléculaire :1070.13CMD178
<p>CMD178 is an important polypeptide that consistently reduces the expression of Foxp3 and STAT5 by inhibiting the IL-2/s IL-2Rα signaling pathway.</p>Formule :C46H59N9O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :850.03SJ10542
CAS :<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Formule :C41H46N12O5SCouleur et forme :SolidMasse moléculaire :818.95JAK2-IN-10
CAS :<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Formule :C33H33D3FN9O2Couleur et forme :SolidMasse moléculaire :612.71SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Formule :C43H45N13O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.96Axltide
CAS :<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formule :C63H107N19O20S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1514.77Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS :<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Formule :C88H138N20O34P2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2082.1JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Formule :C17H14ClN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :355.78JI069
CAS :<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Formule :C15H12Cl2N2O4SDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :387.24JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formule :C30H33FN4O3SCouleur et forme :SolidMasse moléculaire :548.67Pumecitinib
CAS :<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Formule :C17H20N8O2SDegré de pureté :99.94%Couleur et forme :SoildMasse moléculaire :400.46LH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Formule :C29H31F3N6O2SCouleur et forme :SolidMasse moléculaire :584.66JAK2-IN-6
CAS :<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Formule :C14H10ClN3OS2Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :335.83STAT3 degrader-1
CAS :<p>STAT3 Degrader-1 (Compound 295) is a potent degrader of STAT3, utilized in anticancer research [1].</p>Formule :C58H63F5N9O12PSCouleur et forme :SolidMasse moléculaire :1236.2JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Couleur et forme :Odour SolidSTAT5-IN-3
<p>STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer properties. It works by blocking the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites, significantly reducing the expression of the STAT5B protein. This leads to the inhibition of downstream gene transcription, thereby preventing the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 has significant potential in overcoming chemotherapy resistance.</p>Formule :C25H27N5OCouleur et forme :SolidMasse moléculaire :413.51JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Couleur et forme :Odour SolidTYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Couleur et forme :Odour SolidR8-T198wt
CAS :<p>Cell-permeable peptide blocking Pim-1 kinase, halts DU145 cell growth, causes G1 arrest and apoptosis, inert to RPWE-1 cells at 10-20 μM.</p>Formule :C111H211N59O26SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :2820.33Tyk2-IN-22
CAS :<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Formule :C16H16ClN5O2Couleur et forme :SolidMasse moléculaire :345.78OSM-SMI-10B
<p>OSM-SMI-10B, a variant of OSM-SMI-10, inhibits OSM-induced STAT3 activation in cancer cells.</p>Formule :C21H14O7Couleur et forme :SolidMasse moléculaire :378.33JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Degré de pureté :98%Couleur et forme :Odour SolidSJ1008030
CAS :<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formule :C42H43N13O7SCouleur et forme :SolidMasse moléculaire :873.94APTSTAT3-9R
<p>APTSTAT3-9R-9R blocks STAT3 (Ki: 231 nmol/L), hindering cancer cell growth and resistance.</p>Formule :C223H330N80O51Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :4947.51FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :LiquidVB1080
<p>VB1080 (compound 12) is a potent PIM inhibitor with IC50 values of 69.5 µM for PIM1, 4996 µM for PIM2, and 9.88 µM for PIM3. Additionally, VB1080 exhibits cytotoxic properties and possesses anthelmintic activity.</p>Formule :C27H27N3O3Couleur et forme :SolidMasse moléculaire :441.522Neocucurbitacin A
CAS :<p>Neocucurbitacin A (compound 7), a STAT3 inhibitor extracted from the pericarp of Aquilaria crassna, serves as a potential agent for anticancer research [1].</p>Formule :C31H42O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :542.66SJ988497
CAS :<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formule :C36H36N10O5Couleur et forme :SolidMasse moléculaire :688.74JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Formule :C30H32N8O5SCouleur et forme :SolidMasse moléculaire :616.69S-Ruxolitinib
CAS :<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Formule :C17H18N6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :306.37PROTAC TYK2 degradation agent1
CAS :<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formule :C55H69N13O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1056.28TP-5801 TFA
<p>TP-5801 TFA is an orally active inhibitor of TNK1, a non-receptor tyrosine kinase, with an IC50 value of 1.40 nM, demonstrating anti-tumor activity [1].</p>Formule :C26H32BrF3N8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :641.48Deuruxolitinib
CAS :<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Formule :C17H18N6Couleur et forme :SolidMasse moléculaire :314.41HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Formule :C60H69N17O11SCouleur et forme :SolidMasse moléculaire :1236.36MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formule :C23H26N4O2SCouleur et forme :SolidMasse moléculaire :422.54KT-333 diammonium
CAS :<p>KT-333 diammonium functions as a molecular glue that targets and degrades the STAT3 protein. It selectively mediates the degradation of STAT3 via the ubiquitin-proteasome pathway by attaching to STAT3 and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). This compound exhibits strong specificity in degrading STAT3 and demonstrates significant antitumor activity. KT-333 diammonium is applicable in researching hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).</p>Formule :C60H80ClN12O14PSCouleur et forme :SolidMasse moléculaire :1291.84KT-333 ammonium
CAS :<p>KT-333 ammonium (Compound A) acts as a molecular glue that targets and promotes the degradation of the STAT3 protein through the ubiquitin-proteasome system. This compound achieves selective degradation by binding simultaneously to the STAT3 protein and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). It exhibits strong selectivity and efficacy in degrading STAT3, possessing notable antitumor properties. KT-333 ammonium is particularly useful for research on hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) [1].</p>Formule :C60H77ClN11O14PSCouleur et forme :SolidMasse moléculaire :1274.81TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formule :C23H21FN4O2Couleur et forme :SolidMasse moléculaire :404.16485Fulipiftide
CAS :<p>Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). It stimulates the amplification of nuclear stem cell factor+TSPC by activating the ERK2 and STAT3 signaling pathways. Fulipiftide also exhibits anti-inflammatory properties and is applicable in research on acute tendon injuries.</p>Formule :C144H227N41O47Couleur et forme :SolidMasse moléculaire :3284.59DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formule :C25H38N4O3Couleur et forme :SolidMasse moléculaire :442.59SD-2301
CAS :<p>SD-2301 is a PROTAC degrader of STAT3.</p>Formule :C64H80N13O15PS2Couleur et forme :SolidMasse moléculaire :1366.50WDR5 ligand 2
CAS :<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formule :C29H31F3N4O4Couleur et forme :SolidMasse moléculaire :556.576Povorcitinib phosphate
CAS :<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Formule :C23H25F5N7O5PDegré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :605.45STAT3-IN-41
<p>STAT3-IN-41 (Compound 16) is a prodrug of compound 1. It gradually releases compound 1, which inhibits the STAT3 signaling pathway. STAT3-IN-41 exhibits antitumor activity against lung cancer, hepatocellular carcinoma, and pancreatic cancer.</p>Formule :C22H30F3NO7Couleur et forme :SolidMasse moléculaire :477.471Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Couleur et forme :Odour SolidPROTAC STAT3 degrader-2
CAS :<p>PROTAC STAT3 degrader-2 selectively breaks down STAT3 (DC50: 3.54μM, Molm-16) with cancer research potential.</p>Formule :C59H60F2N9O13PCouleur et forme :SolidMasse moléculaire :1172.13Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidAtinvicitinib
CAS :<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Formule :C16H17FN6O3Degré de pureté :99.36%Couleur et forme :SolidMasse moléculaire :360.35CHZ868
CAS :<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Formule :C22H19F2N5O2Degré de pureté :99.38%Couleur et forme :SolidMasse moléculaire :423.42SD-436
CAS :<p>SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.</p>Formule :C58H62F4N9O14PSDegré de pureté :99.34%Couleur et forme :SolidMasse moléculaire :1248.2DTP3
CAS :<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Formule :C26H35N7O5Couleur et forme :SolidMasse moléculaire :525.6Pim-1/2 kinase inhibitor 1
CAS :<p>Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.</p>Formule :C11H9NO3SDegré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :235.26Itacitinib adipate
CAS :<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Formule :C32H33F4N9O5Couleur et forme :SolidMasse moléculaire :699.66Ilunocitinib
CAS :<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Formule :C17H17N7O2SDegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :383.43AK-1690
CAS :<p>AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells and depletes STAT6 proteins in mouse tissues.</p>Formule :C51H56F2N5O11PSDegré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :1016.055,15-DPP
CAS :<p>5,15-Diphenylporphyrin (5,15-DPP) is a selective STAT3-SH2 antagonist with IC 50s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively [1].</p>Formule :C32H22N4Couleur et forme :SolidMasse moléculaire :462.54Ifidancitinib
CAS :<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Formule :C20H18FN5O3Degré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :395.39FLLL32
CAS :<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formule :C28H32O6Degré de pureté :97% - 97.90%Couleur et forme :SolidMasse moléculaire :464.55Filgotinib
CAS :<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Formule :C21H23N5O3SDegré de pureté :98.03% - ≥95%Couleur et forme :SolidMasse moléculaire :425.5RGB-286638 free base
CAS :<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Formule :C29H35N7O4Degré de pureté :98% - 99.91%Couleur et forme :SolidMasse moléculaire :545.63JAK3-IN-6
CAS :<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Formule :C19H18N4O3Degré de pureté :99.94% - 99.94%Couleur et forme :SolidMasse moléculaire :350.37Ritlecitinib
CAS :<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Formule :C15H19N5ODegré de pureté :98.82% - 99.92%Couleur et forme :SolidMasse moléculaire :285.34SHR0302
CAS :<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formule :C18H22N8O2SDegré de pureté :99.11%Couleur et forme :SolidMasse moléculaire :414.48AG490
CAS :<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formule :C17H14N2O3Degré de pureté :98.6% - 99.39%Couleur et forme :Yellow SolidMasse moléculaire :294.3RO8191
CAS :<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Formule :C14H5F6N5ODegré de pureté :98% - 98.85%Couleur et forme :SolidMasse moléculaire :373.21SMI-16a
CAS :<p>SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (</p>Formule :C13H13NO3SDegré de pureté :99.99%Couleur et forme :SolidMasse moléculaire :263.31SAR-20347
CAS :<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Formule :C21H18ClFN4O4Degré de pureté :98.99% - 99.77%Couleur et forme :SolidMasse moléculaire :444.84XL019
CAS :<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formule :C25H28N6O2Degré de pureté :99.19%Couleur et forme :SolidMasse moléculaire :444.53Gandotinib
CAS :<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Formule :C23H25ClFN7ODegré de pureté :99.33% - 99.86%Couleur et forme :SolidMasse moléculaire :469.94Momelotinib HCl
CAS :<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Formule :C23H24Cl2N6O2Couleur et forme :SolidMasse moléculaire :487.38Atractylenolide I
CAS :<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Formule :C15H18O2Degré de pureté :97.55% - 99.92%Couleur et forme :SolidMasse moléculaire :230.3TCS-PIM-1-4a
CAS :<p>SMI-4a, a Pim inhibitor, activates AMPK, halts mTORC1, and kills various myeloid/lymphoid cells (IC50=0.8-40μM).</p>Formule :C11H6F3NO2SDegré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :273.23Peficitinib
CAS :<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Formule :C18H22N4O2Degré de pureté :98.67% - 99.4%Couleur et forme :SolidMasse moléculaire :326.39Tofacitinib Citrate
CAS :<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Formule :C22H28N6O8Degré de pureté :99.19% - 99.75%Couleur et forme :SolidMasse moléculaire :504.49Gusacitinib HCl
CAS :<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Formule :C24H29ClN8O2Couleur et forme :SolidMasse moléculaire :497Ruxolitinib (S enantiomer)
CAS :<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Formule :C17H18N6Degré de pureté :99.37% - 99.79%Couleur et forme :SolidMasse moléculaire :306.36
